Navigation Links
Studies elucidate genetic links between cancer and schizophrenia
Date:12/8/2007

Boca Raton, FL, December 8, 2007 A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia despite having poor diets and high rates of smoking and their parents.

Researchers at the National Institute for Mental Health (NIMH) emphasize that many of the genes associated with schizophrenia are the same as the genes associated with cancer, but that the cells that have these genes use them in opposite ways in the two disorders. While cancer results from changes in the genes that cause cells to go into metabolic overdrive and multiply rapidly, those same genes cause cells in schizophrenia to slow to a crawl.

We found that many of the same genes are involved in schizophrenia as in cancer, but in a yin and yang way. This will provide critical insight into the molecular structure of schizophrenia, said lead researcher and ACNP member Dr. Daniel Weinberger of NIMH. Some of the genes showing this yin-yang effect include NRG1, AKT1, PIK3, COMT, PRODH and ErbB4. While these genes cant be used to predict exactly who will develop these diseases, Dr. Weinberger says they can be used to help determine risk.

Dr. Amanda Law of the University of Oxford, who heads one of the teams working at the NIMH, explored specific genetic pathways that cells use to make basic decisions about their development and their fate.

This is about basic decision making by cellswhether to multiply, move or change their basic architecture, says Dr. Law. Cancer and schizophrenia may be strange bedfellows that have similarities at the molecular level. The differences lie in how cells respond to external stimuli: in cancer the molecular system functions to speed up the cell and in schizophrenia the system is altered in such a way that causes the cell to slow down. Law adds that selective targeting of these pathways may be a potential target in developing treatments for schizophrenia.

Its very curious that a brain disorder associated with very complicated human behavior has at a genetic and cellular level a striking overlap with cancer, a very non-behavior related disorder. Understanding these pathways might provide us with some new strategies for thinking about cancer, said Dr. Weinberger.

Dr. Weinberger added that future research involves using this information to search for therapeutic insights that can reverse these processes, with implications not only for treatment of schizophrenia, but also maybe for cancer as well.

An estimated two million Americans have schizophrenia, a biological condition that affects a persons ability to think clearly, distinguish reality from fantasy, to manage emotions, make decisions and relate to others. The World Health Organization has identified schizophrenia as one of the ten most debilitating diseases affecting humans.


'/>"/>

Contact: Sharon Reis
sreis@gymr.com
202-745-5103
American College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
5. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
6. Studies Prove Exercise Can Heal the Body Mind and Soul
7. Studies Shed New Light on Breast Cancer, Treatment
8. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
9. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: